We are proud to announce that Eagle IP has been ranked once more in Tier 1 (the highest tier) for Patent Prosecution in the IP Stars 2026 Patent Firms Ranking by Managing IP. The rankings cover over 70 jurisdictions worldwide and recognize the top recommended firms for patent filing, prosecution, and disputes work. This Tier 1 placement is a testament to the positive feedback our clients have provided to Managing IP during their annual reviews.

It is with great pride that we have been included in this highest category among just a select few top firms in Hong Kong. We are deeply grateful to Managing IP for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US and Chinese patent law, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我们的过去活动

Recommended Insights

Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement

2024年1月9日
Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号). Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
CN1982128B Figure

2019 CHINA TOP 10 IP CASE: VALEO V. LUCAS, FUKE, & CHEN

2020年6月8日
Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]
Top crossarrow-right